9月4日，诺诚健华港股盘中上涨5.48%，报15.58港元，成交额1.55亿港元。
消息面上，近期多家机构密集看好该股。高盛将其目标价上调至22.71港元并维持买入评级，指出核心产品奥布替尼二季度销售同比增长37%表现强劲；长城国瑞证券、国金证券亦给予买入评级，机构90日目标均价36.73元人民币。此外，公司半年报显示上半年营收11.37亿元，同比增长55.46%，归母净利润2.46亿元，同比扭亏为盈，二季度单季净利润同比增长392.43%。自免管线方面，TYK2抑制剂ICP-488治疗银屑病及Soficitinib治疗特应性皮炎的III期试验均达主要终点，打开长期增长空间。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.